Evidence map›Paper›PMID 33245332›Full record

Trial reportJournal of Crohn's & colitis2021

Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial.

Daniël R Hoekman, Arine M Vlieger, Pieter C Stokkers, Nofel Mahhmod, Svend Rietdijk, Nanne K de Boer, Tim G de Meij, Carla Frankenhuis, Geert R D'Haens, Marc A Benninga

Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Psychological interventions for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Daniël R HoekmanDepartment of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Arine M VliegerDepartment of Pediatrics, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.
Pieter C StokkersDepartment of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Nofel MahhmodDepartment of Gastroenterology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.
Svend RietdijkDepartment of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Nanne K de BoerDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, AG&M Institute, Amsterdam, The Netherlands.
Tim G de MeijDepartment of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Carla FrankenhuisDepartment of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Geert R D'HaensDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Marc A BenningaDepartment of Pediatric Gastroenterology and Nutrition, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Amsterdam University Medical Centers · NLOLVG · NLSt. Antonius Ziekenhuis · NLVrije Universiteit Amsterdam · NL

Funding

ZonMw 171101009
6 · The paper itself

Abstract

BACKGROUND AND

aimsMany inflammatory bowel disease [IBD] patients in remission have persisting symptoms, compatible with irritable bowel syndrome [IBS-type symptoms]. We aimed to compare the effectiveness of gut-directed hypnotherapy vs standard medical treatment [SMT] for IBS-type symptoms in IBD patients.

methodsIn this multicentre, randomized, controlled, open-label trial, patients aged 12-65 years with IBD in clinical remission [global assessment] and biochemical remission [faecal calprotectin ≤100 µg/g, or ≤200 µg/g without inflammation at endoscopy] with IBS according to Rome III criteria were randomized to hypnotherapy or SMT. Primary outcome was the proportion with ≥50% reduction on a visual analog scale for symptom severity, as measured with the Irritable Bowel Syndrome Severity Scoring System [IBS-SSS] at week 40 [i.e. 6 months after finishing the intervention], compared to baseline. Secondary outcomes included total IBS-SSS score, quality of life, adequate relief, IBS-related cognitions, and depression and anxiety scores.

resultsEighty patients were included, of whom 70 received at least one session of the allocated treatment and were included in the modified intention-to-treat-population. Seven patients were excluded because of missing baseline data required for the primary outcome. The primary outcome was met in nine [27%] of 33 patients randomized to SMT and nine [30%] of 30 patients randomized to hypnotherapy [p = 0.81]. Adequate relief was reported in 60% and 40% of subjects, respectively. Exploratory analyses of secondary outcomes revealed no apparent differences between the two treatment groups.

conclusionsHypnotherapy was not superior to SMT in the treatment of IBS-type symptoms in IBD patients. Both treatment strategies are reasonable options from a clinical perspective.

Indexed as

HypnosisAdolescentAdultAgedBiomarkersChildFemaleHumansIrritable Bowel SyndromeMaleMiddle AgedNetherlandsQuality of LifeBiomarkersCrohn’s diseasegut-directed hypnotherapyhypnotherapyIBS-like symptomsIBS-type symptomsinflammatory bowel diseaseirritable bowel syndromeulcerative colitis

Identifiers

PMID33245332
PMCPMC8256629
OpenAlexW3110288953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.